Xeltis Raises €20.5 Million to Advance Regenerative Blood Vessel Technology and Expand Global Growth

These artificial vessels and valves are designed to slowly be replaced by the patient's own healthy tissue over time. This helps the body heal naturally.

The funding came from both new and existing investors. The round was led by Horizon 3 Healthcare, with support from the European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, DaVita, and other current shareholders.

Eliane Schutte, Chief Executive Officer, Xeltis, said, “This fundraising not only enables us to bring our groundbreaking vascular access technology to more European patients, as we continue our successful commercial rollout, but also enables us to advance our aXess™ pivotal trial in the US, prepare for US market launch and continue our other exciting clinical programs, XABG and XPAD. We welcome our new investor Horizon 3 Healthcare and thank them, and our existing investors, for their confidence in Xeltis as we look to bring much-needed alternatives to patients.”

“The data generated by Xeltis to date has been highly compelling and underscores the potential of aXess™ to transform the hemodialysis access landscape and improve patient outcomes. We are impressed by the company’s strong execution and rapid progress and are proud to support Xeltis as it advances aXess™ through US clinical development and European commercialisation, while continuing to expand its broader pipeline of transformative implants,” said Matt McNamara, Chief Investment Officer of Horizon 3 Healthcare.

Founded in 2006, Xeltis develops medical implants that help the body naturally grow new, living blood vessels. These implants are designed for patients who need hemodialysis access or heart and blood vessel replacements.

The company's technology aims to solve the problems of current treatment options by creating stronger and longer-lasting blood vessels that work with the body's natural healing process.

Xeltis uses its proprietary Restorex® platform, which is made from a special polymer implant. Over time, the implant is gradually absorbed by the body and replaced with the patient's own healthy tissue, leaving behind a natural, living blood vessel.

Read Also- Logistics AI Startup 5U AI Raises $3.2M Pre-Seed Funding to Scale Digital Workforce Platform